Topiramate in the treatment of substance-related disorders: A critical review of the literature

Journal of Clinical Psychiatry

Volumn 71, Issue 5, 2010, Pages 634-648

  Shinn, Ann K ^b,c   Greenfield, Shelly F ^a,c  

^a Alcohol and Drug Abuse Research Center   (United States)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALANINE AMINOTRANSFERASE; ALCOHOL; ALPRAZOLAM; ARIPIPRAZOLE; ASPARTATE AMINOTRANSFERASE; CARBAMAZEPINE; CARBOHYDRATE DEFICIENT TRANSFERRIN; CLONIDINE; COCAINE; DIAZEPAM; DISULFIRAM; GAMMA GLUTAMYL HYDROLASE; IBUPROFEN; LAMOTRIGINE; MEMANTINE; METHADONE; METHAMPHETAMINE; MIANSERIN; MIRTAZAPINE; NALTREXONE; NICOTINE; OLANZAPINE; OPIATE; PIROXICAM; TIZANIDINE; TOLPERISONE; TOPIRAMATE; UNINDEXED DRUG; ZOLPIDEM;

ADD ON THERAPY; ADJUVANT THERAPY; ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; BIPOLAR DISORDER; BORDERLINE STATE; COCAINE DEPENDENCE; DIZZINESS; DRUG DEPENDENCE; DRUG DETOXIFICATION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; EATING DISORDER; GENETIC VARIABILITY; HUMAN; HYPOTENSION; INFORMATION RETRIEVAL; INSOMNIA; LABORATORY TEST; LIFE SATISFACTION; MEDLINE; MEMORY DISORDER; NAUSEA; NERVOUSNESS; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PRURITUS; PSYCHOLOGICAL WELL BEING; PSYCHOMOTOR DISORDER; REWARD; SAMPLE SIZE; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING CESSATION; STUDY DESIGN; SUBSTANCE ABUSE; TOBACCO DEPENDENCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

ALCOHOL-RELATED DISORDERS; AMPHETAMINE-RELATED DISORDERS; COCAINE-RELATED DISORDERS; FRUCTOSE; HUMANS; NEUROPROTECTIVE AGENTS; OPIOID-RELATED DISORDERS; SUBSTANCE-RELATED DISORDERS; TOBACCO USE DISORDER;

EID: 77952592220     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08r04062gry     Document Type: Article

References (78)

1. Litten RZ, Fertig J, Mattson M, et al. Development of medications for alcohol use disorders: recent advances and ongoing challenges. Expert Opin Emerg Drugs. 2005;10(2):323-343. (Pubitemid 40695131)
2. Carroll KM, Nich C, Ball SA, et al. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction. 1998; 93(5):713-727. (Pubitemid 28230603)
3. Carroll KM, Nich C, Ball SA, et al. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction. 2000;95(9):1335-1349.
4. George TP, Chawarski MC, Pakes J, et al. Disulfiram versus placebo for cocaine dependence in buprenorphine-maintained subjects: a preliminary trial. Biol Psychiatry. 2000;47(12):1080-1086. (Pubitemid 30336217)
5. Petrakis IL, Carroll KM, Nich C, et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction. 2000;95(2):219-228. (Pubitemid 30111242)
6. Carroll KM, Fenton LR, Ball SA, et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch Gen Psychiatry. 2004;61(3):264-272.
7. Baker JR, Jatlow P, McCance-Katz EF. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007; 87(2-3):202-209. (Pubitemid 46215924)
8. Grassi MC, Cioce AM, Giudici FD, et al. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: a pilot study. Pharmacol Res. 2007;55(2):117-121.
9. Shoptaw S, Yang X, Rotheram-Fuller EJ, et al. Randomized placebo-controlled trial of baclofen for cocaine dependence: preliminary effects for individuals with chronic patterns of cocaine use. J Clin Psychiatry. 2003;64(12):1440-1448. (Pubitemid 41270102)
10. Dackis CA, Kampman KM, Lynch KG, et al. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology. 2005;30(1):205-211. (Pubitemid 40024415)
11. Poling J, Oliveto A, Petry N, et al. Six-month trial of bupropion with contingency management for cocaine dependence in a methadone-maintained population. Arch Gen Psychiatry. 2006;63(2):219-228. (Pubitemid 43213884)
12. Schiffer WK, Gerasimov MR, Marsteller DA, et al. Topiramate selectively attenuates nicotine-induced increases in monoamine release. Synapse. 2001;42(3):196-198.
13. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord. 1998;50(2-3):245-251. (Pubitemid 28551793)
14. Chengappa KN, Rathore D, Levine J, et al. Topiramate as add-on treatment for patients with bipolar mania. Bipolar Disord. 1999;1(1):42-53.
15. McElroy SL, Suppes T, Keck PE, et al. Open-label adjunctive topiramate in the treatment of bipolar disorders. Biol Psychiatry. 2000;47(12): 1025-1033.
16. Calabrese JR, Keck PE Jr, McElroy SL, et al. A pilot study of topiramate as monotherapy in the treatment of acute mania. J Clin Psychopharmacol. 2001;21(3):340-342. (Pubitemid 32452941)
17. Ghaemi SN, Manwani SG, Katzow JJ, et al. Topiramate treatment of bipolar spectrum disorders: a retrospective chart review. Ann Clin Psychiatry. 2001;13(4):185-189. (Pubitemid 34273558)
18. Grunze HCR, Normann C, Langosch J, et al. Antimanic efficacy of topiramate in 11 patients in an open trial with an on-off-on design. J Clin Psychiatry. 2001;62(6):464-468.
19. Bozikas VP, Petrikis P, Kourtis A, et al. Treatment of acute mania with topiramate in hospitalized patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1203-1206. (Pubitemid 35256117)
20. DelBello MP, Kowatch RA, Warner J, et al. Adjunctive topiramate treatment for pediatric bipolar disorder: a retrospective chart review. J Child Adolesc Psychopharmacol. 2002;12(4):323-330. (Pubitemid 36169284)
21. McIntyre RS, Mancini DA, McCann S, et al. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord. 2002;4(3):207-213. (Pubitemid 34591247)
22. Saxena S, Fieve R. Adjunctive open label topiramate in bipolar disorder. Int J Neuropsychopharmacol. 2002;6:56.
23. Vieta E, Torrent C, Garcia-Ribas G, et al. Use of topiramate in treatment-resistant bipolar spectrum disorders. J Clin Psychopharmacol. 2002;22(4):431-435.
24. Berlant J, van Kammen DP. Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry. 2002;63(1):15-20. (Pubitemid 34113481)
25. Berlant JL. Prospective open-label study of add-on and monotherapy topiramate in civilians with chronic nonhallucinatory post-traumatic stress disorder. BMC Psychiatry. 2004;4(1):24.
26. Tucker P, Trautman RP, Wyatt DB, et al. Efficacy and safety of topiramate monotherapy in civilian posttraumatic stress disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2007;68(2):201-206. (Pubitemid 46362640)
27. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 1: improvement in binge and purge measures. J Clin Psychiatry. 2003;64(11):1335- 1341. (Pubitemid 37490239)
28. Hedges DW, Reimherr FW, Hoopes SP, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, pt 2: improvement in psychiatric measures. J Clin Psychiatry. 2003;64(12):1449-1454. (Pubitemid 41270103)
29. Nickel C, Tritt K, Muehlbacher M, et al. Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial. Int J Eat Disord. 2005;38(4):295-300. (Pubitemid 41785844)
30. Appolinario JC, Fontenelle LF, Papelbaum M, et al. Topiramate use in obese patients with binge eating disorder: an open study. Can J Psychiatry. 2002;47(3):271-273. (Pubitemid 34614686)
31. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160(2):255-261.
32. McElroy SL, Shapira NA, Arnold LM, et al. Topiramate in the long-term treatment of binge-eating disorder associated with obesity. J Clin Psychiatry. 2004;65(11):1463-1469.
33. McElroy SL, Hudson JI, Capece JA, et al.Topiramate Binge Eating Disorder Research Group. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039- 1048.
34. Bray GA, Hollander P, Klein S, et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obes Res. 2003;11(6):722-733. (Pubitemid 41151598)
35. Astrup A, Caterson I, Zelissen P, et al. Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects. Obesity (Silver Spring). 2004;12(10):1658-1669. (Pubitemid 41132475)
36. Wilding J, Van Gaal L, Rissanen A, et al. OBES-002 Study Group. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects. Int J Obes Relat Metab Disord. 2004;28(11):1399-1410.
37. Tonstad S, Tykarski A, Weissgarten J, et al. Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension. Am J Cardiol. 2005;96(2):243-251. (Pubitemid 40978583)
38. Stenlöf K, Rössner S, Vercruysse F, et al. OBDM-003 Study Group. Topiramate in the treatment of obese subjects with drug-naive type 2 diabetes. Diabetes Obes Metab. 2007;9(3):360-368.
39. Toplak H, Hamann A, Moore R, et al. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Int J Obes (London). 2007;31(1):138-146. (Pubitemid 46006027)
40. Lin YH, Liu CY, Hsiao MC. Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate. Psychiatry Clin Neurosci. 2005;59(5):613-615. (Pubitemid 41765763)
41. Kim JH, Yim SJ, Nam JH. A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia. Schizophr Res. 2006;82(1): 115-117. (Pubitemid 43202654)
42. Huguelet P, Morand-Collomb S. Effect of topiramate augmentation on two patients suffering from schizophrenia or bipolar disorder with comorbid alcohol abuse. Pharmacol Res. 2005;52(5):392-394. (Pubitemid 41534617)
43. Chiu Y-H, Lee T-H, Shen WW. Use of low-dose topiramate in substance use disorder and bodyweight control. Psychiatry Clin Neurosci. 2007;61(6):630-633.
44. Rubio G, Ponce G, Jiménez-Arriero MA, et al. Effects of topiramate in the treatment of alcohol dependence. Pharmacopsychiatry. 2004;37(1):37-40. (Pubitemid 38230738)
45. Fernandez Miranda JJ, Marina González PA, Montes Pérez M, et al. Topiramate as add-on therapy in non-respondent alcohol dependant patients: a 12 month follow-up study. Actas Esp Psiquiatr. 2007;35(4): 236-242.
46. Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet. 2003;361(9370):1677-1685. (Pubitemid 36577440)
47. Johnson BA, Ait-Daoud N, Akhtar FZ, et al. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry. 2004;61(9):905-912. (Pubitemid 39181080)
48. Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction. 2006;101(11):1561-1568. (Pubitemid 44527187)
49. Johnson BA, Rosenthal N, Capece JA, et al.Topiramate for Alcoholism Study Group. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641-1651.
50. De Sousa AA, De Sousa J, Kapoor H. An open randomized trial comparing disulfiram and topiramate in the treatment of alcohol dependence. J Subst Abuse Treat. 2008;34(4):460-463. (Pubitemid 351609293)
51. Flórez G, García-Portilla P, Álvarez S, et al. Using topiramate or naltrexone for the treatment of alcohol-dependent patients. Alcohol Clin Exp Res. 2008;32(7):1251-1259.
52. Baltieri DA, Daró FR, Ribeiro PL, et al. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction. 2008; 103(12):2035-2044.
53. Miranda R Jr, MacKillop J, Monti PM, et al. Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res. 2008;32(3):489-497. (Pubitemid 351300992)
54. Cagetti E, Baicy KJ, Olsen RW. Topiramate attenuates withdrawal signs after chronic intermittent ethanol in rats. Neuroreport. 2004;15(1): 207-210. (Pubitemid 41615000)
55. Farook JM, Morrell DJ, Lewis B, et al. Topiramate (Topamax) reduces conditioned abstinence behaviours and handling-induced convulsions (HIC) after chronic administration of alcohol in Swiss-Webster mice. Alcohol Alcohol. 2007;42(4):296-300.
56. Rustembegovic A, Sofic E, Kroyer G. A pilot study of Topiramate (Topamax) in the treatment of tonic-clonic seizures of alcohol withdrawal syndromes. Med Arh. 2002;56(4):211-212.
57. Krupitsky EM, Rudenko AA, Burakov AM, et al. Antiglutamatergic strategies for ethanol detoxification: comparison with placebo and diazepam. Alcohol Clin Exp Res. 2007;31(4):604-611.
58. Arbaizar B, Gómez-Acebo I, Llorca J. Decrease in tobacco consumption after treatment with topiramate and aripiprazole: a case report. J Med Case Reports. 2008;2(1):198. (Pubitemid 351891453)
59. Khazaal Y, Cornuz J, Bilancioni R, et al. Topiramate for smoking cessation. Psychiatry Clin Neurosci. 2006;60(3):384-388.
60. Johnson BA, Ait-Daoud N, Akhtar FZ, et al. Use of oral topiramate to promote smoking abstinence among alcohol-dependent smokers: a randomized controlled trial. Arch Intern Med. 2005;165(14):1600-1605. (Pubitemid 41124153)
61. Sofuoglu M, Poling J, Mouratidis M, et al. Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology (Berl). 2006;184(3-4):645-651. (Pubitemid 43255881)
62. Reid MS, Palamar J, Raghavan S, et al. Effects of topiramate on cue-induced cigarette craving and the response to a smoked cigarette in briefly abstinent smokers. Psychopharmacology (Berl). 2007;192(1):147-158. (Pubitemid 46673896)
63. Anthenelli RM, Blom TJ, McElroy SL, et al. Preliminary evidence for gender-specific effects of topiramate as a potential aid to smoking cessation. Addiction. 2008;103(4):687-694.
64. Kampman KM, Pettinati H, Lynch KG, et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug Alcohol Depend. 2004;75(3):233-240. (Pubitemid 38993293)
65. Reis AD, Castro LA, Faria R, et al. Craving decrease with topiramate in outpatient treatment for cocaine dependence: an open label trial. Rev Bras Psiquiatr. 2008;30(2):132-135. (Pubitemid 351955879)
66. Tatsuta T, Kitanaka N, Kitanaka J, et al. Lack of effect of anti-convulsant topiramate on methamphetamine-induced stereotypy and rewarding property in mice. Pharmacol Biochem Behav. 2007;87(1):48-55. (Pubitemid 46855818)
67. Johnson BA, Roache JD, Ait-Daoud N, et al. Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol. 2007;10(1):85-98. (Pubitemid 46122755)
68. Johnson BA, Roache JD, Ait-Daoud N, et al. Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(1): 123-130. (Pubitemid 44959260)
69. Zullino DF, Cottier A-C, Besson J. Topiramate in opiate withdrawal. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(6):1221-1223.
70. Zullino DF, Krenz S, Zimmerman G, et al. Topiramate in opiate withdrawal-comparison with clonidine and with carbamazepine/mianserin. Subst Abus. 2004;25(4):27-33. (Pubitemid 41617683)
71. Cheseaux M, Monnat M, Zullino DF. Topiramate in benzodiazepine withdrawal. Human Psychopharmacology: Clinical & Experimental. 2003;18(5):375-377.
72. Michopoulos I, Douzenis A, Christodoulou C, et al. Topiramate use in alprazolam addiction. World J Biol Psychiatry. 2006;7(4):265-267.
73. Pages KP, Ries RK. Use of anticonvulsants in benzodiazepine withdrawal. Am J Addict. 1998;7(3):198-204.
74. Akhondzadeh S, Hampa AD. Topiramate prevents ecstasy consumption: a case report. Fundam Clin Pharmacol. 2005;19(5):601-602.
75. Láinez MJA, Freitag FG, Pfeil J, et al. Time course of adverse events most commonly associated with topiramate for migraine prevention. Eur J Neurol. 2007;14(8):900-906. (Pubitemid 47106778)
76. Rogawski MA. Update on the neurobiology of alcohol withdrawal seizures. Epilepsy Curr. 2005;5(6):225-230.
77. Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry. 2008;65(2):135-144. (Pubitemid 351222547)
78. Uhl GR, Liu Q-R, Drgon T, et al. Molecular genetics of successful smoking cessation: convergent genome-wide association study results. Arch Gen Psychiatry. 2008;65(6):683-693. (Pubitemid 351787239)